Skip to main content
OpenTrials
Completed

NCT Number: NCT06338956

Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI

For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Dyslipidemias Heart Diseases Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, South Korea

About this study

To investigate the Optimal Attained LDL-C Levels in Patients Who Achieved ≥50% LDL-C Reduction After PCI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients receiving PCI with health check up before and after PCI within 3 years

Exclusion criteria

  • Patients receiving statin before PCI
  • Patients with liver cirrhosis
  • Patients with cancer
  • Patients without prescription of statin
  • Patients with LDL-C <55 mg/dL before PCI

Treatment and study plan

LDL reduction therapy

Drug

LDL reduction therapy

Primary outcomes

  1. MACCE

    Time frame: 10 years after PCI

    major adverse cardiac and cerebrovascular events

Secondary outcomes

  1. Cardiovascular death

    Time frame: 10 years after PCI

    death from cardiovascular cause

  2. Spontaneous myocardial infarction

    Time frame: 10 years after PCI

    MI with hospitalziation

  3. Repeat revascularization

    Time frame: 10 years after PCI

    additional PCI or CABG

  4. Ischemic stroke

    Time frame: 10 years after PCI

    Stoke from ischemic cause

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Acronym: Lipid-PCI

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Apr 1, 2024
Registry last updated
May 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.